Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, Liu X, Lewsley LA, Siddiqui N, Gabra H, Lanchbury JS, Brown R. Stronach EA, et al. Among authors: neff c. Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3. Mol Cancer Res. 2018. PMID: 29724815 Free article.
TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition.
Stone S, Abkevich V, Russell DL, Riley R, Timms K, Tran T, Trem D, Frank D, Jammulapati S, Neff CD, Iliev D, Gress R, He G, Frech GC, Adams TD, Skolnick MH, Lanchbury JS, Gutin A, Hunt SC, Shattuck D. Stone S, et al. Among authors: neff cd. Hum Mol Genet. 2006 Sep 15;15(18):2709-20. doi: 10.1093/hmg/ddl204. Epub 2006 Aug 7. Hum Mol Genet. 2006. PMID: 16893906
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS. Timms KM, et al. Among authors: neff c. Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x. Breast Cancer Res. 2014. PMID: 25475740 Free PMC article.
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Telli ML, et al. Among authors: neff c. Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8. Clin Cancer Res. 2016. PMID: 26957554 Free PMC article. Clinical Trial.
Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.
von Wahlde MK, Timms KM, Chagpar A, Wali VB, Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Lanchbury JS, Hatzis C, Hofstatter E, Pusztai L. von Wahlde MK, et al. Among authors: neff c. Clin Cancer Res. 2017 Mar 1;23(5):1193-1199. doi: 10.1158/1078-0432.CCR-16-0889. Epub 2016 Sep 6. Clin Cancer Res. 2017. PMID: 27601588
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, Hughes E, Sangale Z, Jones J, Hartman AR, Chang PJ, Vinayak S, Wenstrup R, Ford JM. Telli ML, et al. Among authors: neff c. Breast Cancer Res Treat. 2018 Apr;168(3):625-630. doi: 10.1007/s10549-017-4624-7. Epub 2017 Dec 23. Breast Cancer Res Treat. 2018. PMID: 29275435
Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z. Diossy M, et al. Among authors: neff c. Ann Oncol. 2018 Sep 1;29(9):1948-1954. doi: 10.1093/annonc/mdy216. Ann Oncol. 2018. PMID: 29917049 Free PMC article.
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
Telli ML, Chu C, Badve SS, Vinayak S, Silver DP, Isakoff SJ, Kaklamani V, Gradishar W, Stearns V, Connolly RM, Ford JM, Gruber JJ, Adams S, Garber J, Tung N, Neff C, Bernhisel R, Timms KM, Richardson AL. Telli ML, et al. Among authors: neff c. Clin Cancer Res. 2020 Jun 1;26(11):2704-2710. doi: 10.1158/1078-0432.CCR-19-0664. Epub 2019 Dec 3. Clin Cancer Res. 2020. PMID: 31796517
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK. Siedel JH, et al. Among authors: neff c. Gynecol Oncol. 2021 Mar;160(3):777-785. doi: 10.1016/j.ygyno.2020.12.010. Epub 2021 Feb 6. Gynecol Oncol. 2021. PMID: 33563487 Free PMC article.
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling.
Denkert C, Romey M, Swedlund B, Hattesohl A, Teply-Szymanski J, Kommoss S, Kaiser K, Staebler A, du Bois A, Grass A, Knappmeyer C, Heitz F, Solimeno C, Ebel T, Harter P, Marmé F, Jank P, Gaiser T, Neff C, Wagner U, Timms KM, Rodepeter F. Denkert C, et al. Among authors: neff c. J Mol Diagn. 2022 Dec;24(12):1254-1263. doi: 10.1016/j.jmoldx.2022.09.004. Epub 2022 Sep 30. J Mol Diagn. 2022. PMID: 36191839 Free article.
190 results